Compare ALEMBIC with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs DIVIS LABORATORIES - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC DIVIS LABORATORIES ALEMBIC/
DIVIS LABORATORIES
 
P/E (TTM) x 78.6 58.2 135.1% View Chart
P/BV x 6.8 15.6 43.6% View Chart
Dividend Yield % 0.2 0.4 38.3%  

Financials

 ALEMBIC   DIVIS LABORATORIES
EQUITY SHARE DATA
    ALEMBIC
Mar-18
DIVIS LABORATORIES
Mar-19
ALEMBIC/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs721,639 4.4%   
Low Rs341,115 3.0%   
Sales per share (Unadj.) Rs4.7186.3 2.5%  
Earnings per share (Unadj.) Rs6.151.0 12.0%  
Cash flow per share (Unadj.) Rs6.257.3 10.9%  
Dividends per share (Unadj.) Rs0.2016.00 1.3%  
Dividend yield (eoy) %0.41.2 32.5%  
Book value per share (Unadj.) Rs40.7261.8 15.5%  
Shares outstanding (eoy) m267.03265.47 100.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.37.4 152.4%   
Avg P/E ratio x8.727.0 32.1%  
P/CF ratio (eoy) x8.524.0 35.3%  
Price / Book Value ratio x1.35.3 24.8%  
Dividend payout %3.331.4 10.4%   
Avg Mkt Cap Rs m14,139365,592 3.9%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m2075,423 3.8%   
Avg. sales/employee Rs ThNM4,175.1-  
Avg. wages/employee Rs ThNM457.7-  
Avg. net profit/employee Rs ThNM1,141.8-  
INCOME DATA
Net Sales Rs m1,25549,463 2.5%  
Other income Rs m3701,556 23.8%   
Total revenues Rs m1,62551,019 3.2%   
Gross profit Rs m11118,718 0.6%  
Depreciation Rs m381,689 2.2%   
Interest Rs m235 4.9%   
Profit before tax Rs m44218,551 2.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m245,023 0.5%   
Profit after tax Rs m1,63013,527 12.0%  
Gross profit margin %8.937.8 23.4%  
Effective tax rate %5.427.1 20.0%   
Net profit margin %129.827.3 474.8%  
BALANCE SHEET DATA
Current assets Rs m1,86746,501 4.0%   
Current liabilities Rs m5918,468 7.0%   
Net working cap to sales %101.676.9 132.2%  
Current ratio x3.25.5 57.5%  
Inventory Days Days94131 72.1%  
Debtors Days Days7486 85.7%  
Net fixed assets Rs m1,79125,797 6.9%   
Share capital Rs m534531 100.6%   
"Free" reserves Rs m10,32468,962 15.0%   
Net worth Rs m10,85869,493 15.6%   
Long term debt Rs m410-   
Total assets Rs m11,59180,383 14.4%  
Interest coverage x260.9531.0 49.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.10.6 17.6%   
Return on assets %14.116.9 83.4%  
Return on equity %15.019.5 77.1%  
Return on capital %15.226.7 56.8%  
Exports to sales %1.50-   
Imports to sales %21.024.6 85.2%   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m26312,187 2.2%   
Fx inflow Rs m1941,238 0.0%   
Fx outflow Rs m26412,405 2.1%   
Net fx Rs m-24428,833 -0.8%   
CASH FLOW
From Operations Rs m2369,543 2.5%  
From Investments Rs m-224-6,854 3.3%  
From Financial Activity Rs m-27-2,459 1.1%  
Net Cashflow Rs m-15230 -6.4%  

Share Holding

Indian Promoters % 64.0 52.0 123.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.8 1.7%  
FIIs % 9.7 19.0 51.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 17.2 151.7%  
Shareholders   54,701 31,796 172.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare ALEMBIC With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; JSW Steel and Hindalco Among Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


May 11, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - NOVARTIS COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS